(Q45230224)

11 December 2017

title

Early withdrawal from cervical cancer screening: the question of cost-effectiveness (English)

1 reference

11 December 2017

main subject

cervix uterine cancer

1 reference

Z Philips

1

1 reference

11 December 2017

D K Whynes

series ordinal

2

1 reference

11 December 2017

publication date

1 September 2001

1 reference

European Journal of Cancer

11 December 2017

published in

1 reference

11 December 2017

volume

37

1 reference

11 December 2017

issue

14

1 reference

11 December 2017

page(s)

1775-1780

1 reference

Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900199-X

7 January 2021

Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900199-X

7 January 2021

Cost-effective policies for cervical cancer screening. An international review

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900199-X

7 January 2021

Economic aspects of cervical cancer screening.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900199-X

7 January 2021

A cost-effectiveness analysis of cervical cancer screening: health policy implications.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900199-X

7 January 2021

Is it cost effective to introduce screening programmes for colorectal cancer? Illustrating the principles of optimal resource allocation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900199-X

7 January 2021

Costs and benefits of cervical screening. III. Cost/benefit analysis of a call of previously unscreened women

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900199-X

7 January 2021

Costs and benefits of cervical screening. II. Is it worthwhile reducing the screening interval from 5 to 3 years?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900199-X

7 January 2021

Cervical screening interval: costing the options in one health authority

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900199-X

7 January 2021

Rationale for stopping cervical screening in women over 50.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900199-X

7 January 2021

The value of cervical screening in women over 50 years of age--time for a multicentre audit

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900199-X

7 January 2021

Withdrawing low risk women from cervical screening programmes: mathematical modelling study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900199-X

7 January 2021

Cytological screening and management of abnormalities in prevention of cervical cancer: an overview with stochastic modelling

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900199-X

7 January 2021

Stage-specific treatment costs for cervical cancer in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900199-X

7 January 2021

Costs and benefits of cervical screening. I. The costs of the cervical screening programme

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900199-X

7 January 2021

Human papillomavirus testing in primary cervical screening.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900199-X

7 January 2021

Limits to rationality: economics, economists and priority setting

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900199-X

7 January 2021

10.1016/S0959-8049(01)00199-X

Identifiers

DOI

1 reference

11 December 2017

1 reference